Defyrus Overview
- Year Founded
-
2008
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Defyrus General Information
Description
Developer of drugs for infectious viral diseases designed to countermeasure bioterrorist threats and emerging diseases. The company's drugs fight infectious viral diseases worldwide for public health and biodefence missions, enabling patients to get products that naturally stimulate the human immune response.
Contact Information
Website
www.defyrus.comCorporate Office
- 2 Bloor Street West
- Suite 2602
- Toronto, Ontario M4W 3E2
- Canada
Corporate Office
- 2 Bloor Street West
- Suite 2602
- Toronto, Ontario M4W 3E2
- Canada
Defyrus Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Jul-2020 | Completed | Out of Business | |||
| 3. Later Stage VC | 01-Jan-2019 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 01-Jan-2018 | $3.72M | Completed | Startup | ||
| 1. Early Stage VC (Series A) | 23-Oct-2008 | $3.72M | $3.72M | Completed | Startup |
Defyrus Patents
Defyrus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-2764759-A1 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | Inactive | 09-Jun-2009 | ||
| EP-2440251-A1 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | Inactive | 09-Jun-2009 | ||
| EP-2440251-A4 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | Inactive | 09-Jun-2009 | ||
| US-20110000480-A1 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | Active | 09-Jun-2009 | ||
| US-20130315952-A1 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | Inactive | 09-Jun-2009 | A61K38/212 |
Defyrus Investments (1)
Defyrus’s most recent deal was a Joint Venture with Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical). The deal was made on 29-Jul-2013.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) | 29-Jul-2013 | Joint Venture | Buildings and Property |
Defyrus FAQs
-
When was Defyrus founded?
Defyrus was founded in 2008.
-
Where is Defyrus headquartered?
Defyrus is headquartered in Toronto, Canada.
-
What industry is Defyrus in?
Defyrus’s primary industry is Drug Discovery.
-
Is Defyrus a private or public company?
Defyrus is a Private company.
-
What is Defyrus’s current revenue?
The current revenue for Defyrus is .
-
How much funding has Defyrus raised over time?
Defyrus has raised $3.72M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process